SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised full-year revenue outlook, attributed to stronger demand for Amtagvi and Proleukin, is driving the sharp rally and renewed attention to its commercial growth. Traders are broadly bullish, with some attributing the move to short covering and anticipating lung-cancer data, while others caution about a pullback or possible share dilution.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors 24-month HOPE-3 extension data showing slower upper-limb decline after patients switched to deramiocel is driving attention and an after-hours share jump. Many traders view the results as supportive of FDA approval, while others caution that the data may not resolve the agencys concerns over trial analysis and efficacy.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vandas positive Phase 3 results for Hetlioz in delayed sleep-wake phase disorder are driving attention, with the trial meeting its primary endpoint and the company planning to pursue an additional FDA indication. Traders are largely celebrating the readout and potential commercial opportunity, while some caution that approval and revenue impact remain uncertain.

Armada Acquisition Corp. II is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combinations with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Miami, FL.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Attention centers on Evernorths Armada SPAC combination and transition to XRPN, positioning the company as a publicly traded XRP treasury vehicle. Traders are enthusiastic about XRP-linked exposure and warrants, while others question the valuation and flag crypto volatility and SPAC-related risks.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion is dominated by the ongoing Iran conflict, uncertainty over negotiations and the Strait of Hormuz, and concerns that elevated oil and diesel costs could weigh on markets and consumers. Reactions are sharply divided over Trumps handling of the conflict, while some traders also question DJTs business fundamentals and others post bullish calls.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCNs sharp bounce has traders calling for a breakout and pointing to Zebecs payroll and payments partnerships as a longer-term adoption story. Speculation about Robinhood or BlackRock involvement is unconfirmed, and skeptics question whether the move can hold amid a history of weak follow-through.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Traders are focused on the August PCE inflation report and what it could mean for Treasury yields and the Feds next rate decision, with some expecting cooler data to support a rebound and others bracing for renewed selling. Rising-yield concerns and quarter-end trading are adding to the choppy price action and debate over whether the market will recover or extend its losses.

Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is chiefly being discussed as a broad-market, long-term buy-and-hold core, with traders praising diversification and steady accumulation. Others warn that the total-market fund remains exposed to concerns about elevated tech and AI valuations, interest rates, and broader market volatility, while some investors continue to favor buying dips.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Buyout speculation dominates, with traders pointing to BRIUMVIs commercial growth and the potential of its subcutaneous formulation and pipeline as reasons a larger pharma company might pursue TG Therapeutics. No acquisition is confirmed; bullish expectations are balanced by uncertainty around a deal and debate over valuation, while investors also watch for upcoming clinical updates.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desks prolonged selloff is drawing attention amid concerns about slowing revenue growth, weak guidance, and pressure on programmatic advertising budgets, with traders also citing competition from Amazon and AI-driven changes. The community is sharply divided between bearish views that the business and management are in decline and bullish arguments that its cash generation and steep drop may leave room for a recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PSRHF Actually, I wouldn&#39;t be surprised if they post another 30 - 60 day extension. Why? New CFO onboard has to give his ultimate approval. He literally just got here and may need more time to satisfy himself (and others) that all of the terms are beneficial to Pulsar. Respectfully, I think a few here are placing too much emphasis on this specific date. Look, production is still OVER 12-14 months away with lots to do before the new facility is even necessary. Yes, they need lead time to manufacture the product. That said, it&#39;s more important the terms are right for Pulsar. Bottom line, as long as they have a signed agreement by the end of November, everything is fine and on time. The terms mean way more than when it is signed and the CFO is a main cog in the decision making process. He simply may need another month or so to sign off. No big deal. I have no knowledge IF it will be extended, just won&#39;t be concerned IF it is extended to November.

Larr E

Jimmy D

Monk

$PSRHF So  what is  everyone’s  thought  on  if  we  will  hear  an  announcement on  the  plant  by  Wednesday  ?  Any  concerns  that  they  will  not   announce an  agreement,  or  if  they  extend  the  time  ?  Also  curious on  if  they  have  gotten  a  drilling contract  lined  up.  The  web  site  still  says  they  are  on    for  September 30  ????

StockTwits Web

Pulsar Helium Inc

R G A

 Actually, I wouldn't be surprised if they post another 30 - 60 day extension. Why? New CFO onboard has to give his ultimate approval. He literally just got here and may need more time to satisfy himself (and others) that all of the terms are beneficial to Pulsar. Respectfully, I think a few here are placing too much emphasis on this specific date. Look, production is still OVER 12-14 months away with lots to do before the new facility is even necessary. Yes, they need lead time to manufacture the product. That said, it's more important the terms are right for Pulsar. Bottom line, as long as they have a signed agreement by the end of November, everything is fine and on time. The terms mean way more than when it is signed and the CFO is a main cog in the decision making process. He simply may need another month or so to sign off. No big deal. I have no knowledge IF it will be extended, just won't be concerned IF it is extended to November.

David Jones

@djones4396 If  that  is going  to  be  the  scenario then  I  would think  they  would  have  announced it  already  ???

 If  that  is going  to  be  the  scenario then  I  would think  they  would  have  announced it  already  ???

@Restless484 Hey Restless. First, I&#39;m not more patient, simply averaging down with limit orders in increments. Second, they have no reason to announce until the 30th. My main point is too much emphasis is being placed on a signing date that doesn&#39;t matter nearly as much as the meat and potatoes inside the deal. If Chart finances the bulk of the cost, that is a Home Run for us. Now that&#39;s what really matters.

Jerel Kerby

 Hey Restless. First, I'm not more patient, simply averaging down with limit orders in increments. Second, they have no reason to announce until the 30th. My main point is too much emphasis is being placed on a signing date that doesn't matter nearly as much as the meat and potatoes inside the deal. If Chart finances the bulk of the cost, that is a Home Run for us. Now that's what really matters.

@djones4396  need some good news by the 30th  this is a joke  i am down from 1.2   i refuse to buy bc no info!   will sell next week if no news

  need some good news by the 30th  this is a joke  i am down from 1.2   i refuse to buy bc no info!   will sell next week if no news

nunya

@stockmasster You do you. Sorry you came in at the higher price but Pulsar management has done nothing wrong. Profit taking has brought share price to where it is now. Expiring warrants were activated and sold to make a quick profit rather than waiting until production. This is all part of the business cycle of an exploration company turning towards production. Happens all the time.

StockTwits for iOS

 You do you. Sorry you came in at the higher price but Pulsar management has done nothing wrong. Profit taking has brought share price to where it is now. Expiring warrants were activated and sold to make a quick profit rather than waiting until production. This is all part of the business cycle of an exploration company turning towards production. Happens all the time.

@djones4396 I’m thinking of selling and just watching it for awhile.  Will wait until next week to decide. I’ve been in since 2024…

 I’m thinking of selling and just watching it for awhile.  Will wait until next week to decide. I’ve been in since 2024…

Marc Nance

@Vincerum Best of luck to you. I’ll buy those shares at this price. Deal.

 Best of luck to you. I’ll buy those shares at this price. Deal.